Seelos Therapeutics to Participate in Two Investor Conferences in August

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) announced its participation in two upcoming investor conferences: the BTIG Virtual Biotechnology Conference on August 9-10 and the Canaccord Growth Conference on August 11-12. CEO Raj Mehra will present updates on the company's clinical programs, including the registrational study of SLS-002 for major depressive disorder (clinical trial NCT04669665), CRISPR-based therapies, and the SLS-005 Phase IIb/III study in ALS. These presentations aim to inform investors about Seelos's advancements in addressing central nervous system disorders.

NEW YORK, July 14, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will participate in two investor conferences: the BTIG Virtual Biotechnology Conference on August 9^th and 10^th and the Canaccord Growth Conference on August 11^th and 12^th.

Raj Mehra, Ph.D., Chairman and CEO, will present and host one on one meetings to provide a corporate update and overview of the company's programs, specifically Part 2 of the recently initiated registrational study of SLS-002 (intranasal racemic ketamine) in Adults with Major Depressive Disorder at imminent risk of suicide (NCT04669665), the recently released in vivo data utilizing CRISPR-dCas9 gene therapy technology where a single dose of SLS-004 produced therapeutically desirable reductions in SNCA mRNA and SNCA protein expressions which are implicated as highly significant risk factors in Parkinson's disease, and the upcoming initiation of the SLS-005 Phase IIb/III pivotal study in amyotrophic lateral sclerosis (ALS) in the Healey ALS Platform Trial.

BTIG Virtual Biotechnology Conference
Presentation: Tuesday, August 10^th from 11:00-11:25am ET

Canaccord Growth Conference  
Presentation: Wednesday, August 11^th from 1:00-1:25pm ET

If you or a loved one are having thoughts of suicide, please seek immediate medical help, go to your nearest emergency room, or call the National Suicide Prevention Lifeline at 1-800-273-8255.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the anticipated Company discussion topics at the BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference, including proposed disclosure regarding Part 2 of Seelos' recently initiated registrational study of SLS-002 (intranasal racemic ketamine) in adults with major depressive disorder at imminent risk of suicide (NCT04669665), the recently released in vivo data utilizing CRISPR-dCas9 gene therapy technology, and Seelos' proposed upcoming initiation of the SLS-005 Phase IIb/III pivotal study in amyotrophic lateral sclerosis (ALS) in the Healey ALS Platform Trial. These statements are based on Seelos' current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business include, but are not limited to, the risk of not successfully executing or continuing its preclinical and clinical studies and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials, the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos' periodic filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
www.seelostherapeutics.com 
http://twitter.com/seelostx 
http://www.linkedin.com/company/seelos 

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-in-august-301332924.html

SOURCE Seelos Therapeutics, Inc.

FAQ

When will Seelos Therapeutics participate in the BTIG Virtual Biotechnology Conference?

Seelos Therapeutics will participate in the BTIG Virtual Biotechnology Conference on August 9-10, 2021.

What will Seelos Therapeutics present at the Canaccord Growth Conference?

At the Canaccord Growth Conference, Seelos Therapeutics will present updates on its clinical programs, including SLS-002 for major depressive disorder.

What is SLS-002 and its significance?

SLS-002 is an intranasal ketamine treatment for adults with major depressive disorder at imminent risk of suicide, currently in registrational study NCT04669665.

What are the key dates for Seelos's presentations in August 2021?

Seelos will present on August 10 at the BTIG Conference from 11:00-11:25 AM ET and on August 11 at the Canaccord Conference from 1:00-1:25 PM ET.

What is the focus of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases, targeting conditions like ALS and Parkinson's disease.